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Summary, conclusions and future perspectives
Colorectal cancer (CRC) is the second cause of cancer related deaths in the western world. 
Although improvements have been made in surgical techniques and the development of 
new chemotherapeutic modalities, 5-year survival rates are still around 60 % 1, leaving 
ample room for improvement. Nevertheless, progress is being made in various fields 
of investigation. Before summarising the studies performed in this thesis, some recent 
developments in colorectal cancer research are discussed below, which may help to put 
things in perspective.
One area of research is dedicated to improve early detection of colorectal cancer or 
its precursor lesion, the adenoma, for example by screening the general population 
and surveillance of high-risk populations. The latter include subjects with the CRC 
predisposition syndromes Familial Adenomatous Polyposis (FAP) and Hereditary Non-
Polyposis Colorectal Cancer (HNPCC), subjects with a family history of CRC, patients with 
previous adenomas or CRC or patients with longstanding inflammatory bowel disease. 
Efforts are made to develop strategies to better identify subjects at risk for HNPCC. An early 
diagnosis of patients with HNPCC is particularly important since periodic colonoscopic 
screening has been shown to improve mortality in HNPCC patients.
With respect to current screening procedures, several options are available, including 
faecal occult blood testing, flexible sigmoidoscopy and colonoscopy, each of which has 
its advantages and disadvantages. Potential future screening modalities include virtual 
colonoscopy, serum proteomics and the detection of molecular abnormalities in stool 
samples 1. A related area of study is further improvement in endoscopic detection techniques 
of early neoplasia, such as high-magnification chromoscopic colonoscopy.
Next, the potential of chemopreventive measures is increasingly being recognised, again 
especially in high-risk populations. Chemoprevention is the use of pharmacological or 
natural agents to prevent the development of cancer or precancerous lesions. Although 
there is evidence that certain non-steroidal anti-inflammatory drugs (NSAIDs), calcium 
and ursodeoxycholic acid reduce the risk of adenoma or carcinoma development, the effects 
are incomplete and there is a need for regimens with better efficacy. A promising strategy 
lies in combining different chemopreventive agents. Such an approach in the animal model 
of FAP, using the combination of a NSAID with an epidermal growth factor receptor 
(EGFR) kinase inhibitor, showed encouraging results 2. The efficacy of similar combination 
regimens, combining NSAIDs with other anticancer drugs, needs further exploration.
Further, efforts are made to increase the efficacy of chemotherapy. Chemotherapy in 
CRC is used in the adjuvant setting in patients with stage III colon tumours and subject of 
study in stage II/III rectal cancer. In the palliative setting, chemotherapy is given in patients 
with stage IV colorectal cancer. The benefit of adjuvant chemotherapy in stage II colon 
cancer patients is controversial, but there appears to be a high-risk subpopulation that may 
benefit. Attempts are being made to identify genetic or protein markers in stage II colon 
cancer patients that predict recurrence 3 and in stage II/III patients to predict sensitivity to 
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chemotherapy 4. It is expected that newly developed genomic and proteomic approaches 
may provide more sensitive markers or indicators of response than current biochemical, 
immunohistochemical or morphological methods. Built on an improved understanding 
of the molecular biology of the disease, advancement in the treatment of CRC is also 
being made by the identification of several molecular targets in colon tumours, potentially 
amenable for directed specific therapies. It can be expected that such a strategy results 
in direct interference with the cellular pathway involved, with less toxicity compared to 
the toxicity associated with the less specific effect of chemotherapy. Recently, the first of 
such compounds have been introduced into clinical practice, in particular the management 
of advanced CRC, namely antibodies directed against EGFR and the vascular endothelial 
growth factor respectively 5,6. Increasing knowledge of the molecular events characterising 
colorectal carcinogenesis will allow the development of novel therapies aiming at specific 
molecular targets.
It is known that the development of CRC is characterised by a sequence of events during 
which normal colonic epithelium gradually transforms to carcinoma, in most cases via 
the development of colorectal adenomas, the so-called adenoma-carcinoma sequence. The 
adenoma-carcinoma sequence is driven by an accumulation of molecular (epi)genetic 
alterations causing progressive disorders in cell growth, differentiation and apoptosis. 
Apoptosis, or programmed cell death, plays an important role in the development and 
maintenance of tissue homeostasis. Multicellular organisms also use apoptosis to 
eliminate potentially dangerous cells, such as genetically damaged cells, including tumour 
cells. Abnormalities in apoptotic function have been identified as contributing events in 
the pathogenesis of colorectal cancer. Furthermore, resistance to apoptosis induction by 
chemotherapeutic drugs or radiotherapy frequently hampers its efficacy in the treatment of 
established tumours.
During apoptosis, a complex death program is initiated that ultimately leads to the 
fragmentation of the cell. The death program can be induced by two major apoptosis 
signalling pathways namely the ‘extrinsic’ and the ‘intrinsic’ pathway. The extrinsic 
pathway is initiated by triggering cell death receptors on the cell surface, leading to 
activation of the intracellular apoptotic machinery. The intrinsic pathway of apoptosis is 
initiated via the mitochondria by cellular stress, for example following DNA damage caused 
by chemotherapeutic drugs and radiation. Mitochondria induce apoptosis by releasing 
cytochrome-c into the cytosol, which causes the assemby of a multiprotein caspase-activating 
complex, known as the apoptosome. Among the regulators of the intrinsic pathway are Bcl-
2 protein family members and inhibitors of apoptosis proteins (IAPs). The elucidation of 
the molecular mechanisms regulating these processes is of primary interest as this may 
guide specific targeted therapies.
Tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a 
transmembrane protein belonging to the TNF superfamily. TRAIL triggers the extrinsic 
apoptotic pathway by binding to its membrane-bound death receptors DR4 and DR5, which 
transmit an apoptotic signal via their intracellular death domains. TRAIL can also bind to 
decoy receptors DcR1 and DcR2 that are unable to initiate an apoptotic signal. Although 
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the physiological role of TRAIL is not exacty known, there are data suggesting a role in 
immunomodulation. In vitro, TRAIL induces apoptosis in a wide variety of cancer cell 
lines but not in normal cells. Preclinical data in mice and nonhuman primates have shown 
that recombinant TRAIL induces tumour regression without serious systemic toxicity. 
Therefore, TRAIL is considered a promising new anti-cancer agent.
The aims of this thesis were to clarify the changes occurring in the degree of apoptosis 
during the gradual development of colorectal cancer. Furthermore, the potential of TRAIL 
as a therapeutic agent was investigated in colorectal adenomas and carcinomas. Tumours 
were studied from patients with a sporadic background as well as from FAP and HNPCC 
patients. Finally, mechanisms behind the chemopreventive action of the NSAID sulindac 
on colorectal epithelial cells were studied, as recent data suggested a mechanism involving 
TRAIL mediated apoptosis.
Following a brief introduction and outline of this thesis in Chapter 1, current knowledge 
of mechanisms of apoptosis and changes in the degree of apoptosis in the development 
of colorectal cancer was reviewed in Chapter 2. Although there is a multitude of studies 
available on apoptosis in colon tissue at different stages of colorectal cancer development, 
results from these studies are contradictory. Considerable controversy exists as to whether 
the frequency of apoptosis increases or decreases during the adenoma-carcinoma 
sequence. Therefore, a systematic review of all available studies, which addressed changes 
in frequency, and distribution of apoptosis in colon epithelium was performed. Studies 
were included if either normal or neoplastic colonic epithelium, or both, was examined. A 
PUBMED search revealed 53 articles. Several aspects from these articles were studied such 
as methods used to determine apoptotic cell death, frequency of apoptosis and locoregional 
distribution of apoptotic cells in normal mucosa, adenomas and carcinomas, correlations 
between the degree of apoptosis and proliferation and the prognostic significance of the 
degree of apoptosis in colorectal cancer.
There was a wide variety in the methods used to determine apoptotic cells in the reviewed 
studies. Most studies had used terminal deoxyribonucleotidyl transferase-mediated nick 
end labelling (TUNEL, n = 29). Other methods used were in situ end labelling (ISEL, n = 7), 
morphology by light microscopy (n = 7), TUNEL or ISEL in conjunction with morphology by 
light microscopy (n = 9), ISEL in conjunction with morphology by electron microscopy (n = 
1), morphology by light microscopy in conjunction with electron microscopy (n = 2) and the 
recently developed method of detection of cleaved cytokeratin 18 by immunohistochemistry 
(n = 2). Caspase-cleaved cytokeratin 18 is an early marker of apoptosis that can be recognised 
in epithelial cells using an antibody (M30) directed against this neo-epitope. Percentages 
of apoptotic cells (apoptotic indices) reported with these methods varied widely. This 
variation is probably partly due to a major limitation of the TUNEL and ISEL methods, i.e. 
false positive marking of necrotic cells in addition to apoptotic cells. Others have already 
seriously questioned the applicability of the TUNEL method to evaluate apoptotic cell death 
in the gastrointestinal tract. Although recently new methods of identifying apoptotic cells 
with higher specificity have been developed, such as M30 immunoreactivity, few studies 




Concerning the degree of apoptosis in normal mucosa, reported apoptotic indices varied 
between 0.11 and 11 %. It was noted that in most studies sections of normal colonic mucosa 
were in fact retrieved from macroscopic normal tissue adjacent to adenomas or carcinomas 
and one could argue whether this represents truly normal epithelium. One study revealed 
that apoptosis in normal mucosa obtained from resection margins indeed differed from 
genuinely normal mucosa, which warrants caution when interpreting studies on apoptosis 
in normal colonic mucosa. When studying the transition from normal colonic mucosa 
to adenomas, most studies indicated a shift towards higher apoptotic indices. The real 
controversy centres on the transition from adenoma to carcinoma. Most studies reported 
that the frequency of apoptotic cell death in carcinomas was higher than in adenomas. 
However, in other studies, no differences or even opposite results were found. Concerning 
the distribution of apoptotic cells during the adenoma-carcinoma sequence, there was 
general agreement that in adenomas apoptosis predominates at the base of the crypt, 
with proliferative activity prevailing at the luminal surface. This is a complete reversal of 
the pattern seen in normal epithelium. With respect to the correlation between rates of 
apoptosis and proliferation in adenomas and carcinomas, again conflicting results were 
obtained. Some studies indicated a correlation between the two, whereas others did not. 
Regarding the prognostic value of apoptotic indices it was found that most studies suggest 
that colorectal tumours with high apoptotic indices were associated with better prognosis 
and survival.
Given the limitations mentioned earlier of the techniques most often used for the 
detection of apoptotic cells, TUNEL and ISEL, a recently developed technique to investigate 
apoptosis in colorectal tissue was studied in Chapter 3. The method used, assessing M30 
immunoreactivity, is based on recognition in epithelial cells of caspase-cleaved cytokeratin 
18 which is an early and specific marker of apoptosis. The technique was validated against the 
gold standard of identification of apoptotic cells. i.e. by morphological criteria. Following the 
observation from Chapter 2 that most studies on apoptosis in normal colorectal epithelium 
were in fact performed in macroscopic normal tissue adjacent to adenomas or carcinomas, 
it was investigated whether apoptotic indices differ between normal mucosa obtained from 
resection margins and genuinely normal mucosa. Paraffin sections of normal colonic 
mucosa (n = 30), normal mucosa obtained from resection margins from carcinomas 
(n=30), colorectal adenomas (n = 84) and carcinomas (n = 40) were studied. Apoptosis of 
epithelial cells was assessed by M30 immunoreactivity as well as by morphological criteria 
and expressed as a proportion of the total number of cells counted (apoptotic index).
Mean apoptotic indices assessed by M30 immunoreactivity were 0.18 ± 0.04 % in normal 
mucosa, 0.42 ± 0.04 % in adenomas and 1.97 ± 0.24 % in carcinomas. Apoptotic indices 
determined by morphological criteria were 0.23 ± 0.03 %, 0.62 ± 0.06 % and 1.78 ± 0.19 
%, respectively. Apoptotic counts were higher in normal mucosa obtained from resection 
margins than in genuinely normal mucosa (p < 0.0001). There was a good correlation 
between apoptotic indices obtained by M30 immunoreactivity and morphological criteria 
(r = 0.71, p < 0.01). These findings support the use of the M30 method in the study of 
apoptosis in colorectal tissues.
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To investigate the potential use of TRAIL or TRAIL receptor agonists as therapeutic 
agents in colorectal neoplasms, the expression of the four membrane-bound TRAIL 
receptors DR4, DR5, DcR1 and DcR2 was studied in colon tissue sections of different stages 
of colon cancer development, i.e. normal colon, adenomas and carcinomas. The expression 
and localisation of TRAIL and its receptors were investigated by immunohistochemistry 
in normal mucosa (n = 10), adenomas (n = 19) and carcinomas (n = 21). Tissues were 
obtained from patients with a sporadic background of their disease. In addition, correlations 
between expression of TRAIL and its receptors and the degree of apoptosis (assessed by 
M30 immunoreactivity) and histopathological characteristics were explored. The results are 
described in Chapter  4.
In normal mucosal epithelial cells, TRAIL and TRAIL receptor expression was observed. 
In adenomas and carcinomas, expression of all four receptors was seen. However, TRAIL 
expression was lost in a subset of colorectal tumours in comparison to adjacent normal 
mucosa. This occurred more frequently in carcinomas than in adenomas (p < 0.05). 
Intensity of DR4 and DR5 staining was stronger in neoplastic cells compared to adjacent 
normal epithelial cells, and was accompanied by a higher degree of apoptosis. No differences 
were found between neoplastic and normal cells regarding DcR1 and DcR2 expression. No 
correlations were found between TRAIL or TRAIL receptor expression and histopathological 
characteristics. The stronger expression of DR4 and DR5 in neoplastic cells as opposed to 
normal cells holds promise for the future use of TRAIL or TRAIL receptor agonists as 
therapeutic agents in colon neoplasms.
Given these encouraging results in patients with sporadic disease, the investigations were 
expanded to tissues obtained from patients with FAP and HNPCC, described in Chapter  5. 
Expression of DR4 and DR5 was studied using immunohistochemistry in colorectal 
adenomas and carcinomas from patients with sporadic disease (n = 74 and 56 respectively), 
FAP (n = 41 and 4 respectively) and HNPCC (n = 50 and 21 respectively). In addition, 
sporadic tumours with microsatellite instability (MSI) were studied, to examine the role 
of BAX gene mutations. BAX was reported to play a role in sensitivity to TRAIL-mediated 
apoptosis in vitro and colorectal tumours with MSI are prone for mutations in the BAX 
gene. The presence of BAX mutations in MSI positive tumours could potentially limit the 
use of TRAIL or TRAIL receptor agonists. Carcinomas with high frequency MSI (MSI-H, 
n = 42, of which 27 sporadic and 15 HNPCC-associated) were analysed for apoptotic cell 
death, assessed by M30 immunoreactivity, and BAX mutations.
Immunohistochemistry revealed that most adenomas from all three patient groups 
expressed DR4 and DR5. Most carcinomas expressed DR4, except for six cases, all with 
mucinous histology. All carcinomas, including those with mucinous histology, showed 
DR5 expression. BAX mutations were found in 6 out of 42 MSI-H cancers, with similar 
apoptotic indices and expression of DR4, DR5 and TRAIL in BAX mutant and BAX wild-type 
cases. These data do not support the presence of BAX inactivation as a critical mechanism 
in vivo to evade apoptosis in MSI-H tumours. Taken together, these results indicate that 
selectively targeting TRAIL death receptors in sporadic and hereditary settings has potential 
as prevention or treatment strategy.
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It is important to identify prognostic factors that can help to develop new patient-tailored 
treatment strategies for CRC patients. Resistance of tumour cells to induction of apoptosis 
is a limiting factor in the efficacy of chemotherapeutic treatment of colon cancer. In vitro, 
chemotherapy and recombinant human (rh) TRAIL were shown to act synergistically on 
induction of apoptosis in colon cancer cells. The prognostic significance of expression of 
TRAIL, DR4 and DR5 on overall and disease free survival and disease recurrence was studied 
and described in Chapter 6. Tissue microarrays were constructed containing tumour tissue 
of 376 stage III colon cancer patients who had participated in an adjuvant chemotherapy 
study in the past 7. These arrays were analysed by immunohistochemistry for TRAIL, DR4 
and DR5 expression. Median follow-up was 43 months. Kaplan-Meier survival analysis and 
Cox proportional hazard analysis with adjustment for treatment arm, age and gender was 
performed.
Most colon cancers showed high expression of TRAIL (82.8 % of cases), DR4 (91.7 %) and 
DR5 (87.1 %). High DR4 expression was associated with worse overall survival {odds ratio 
(OR; 95 % CI) = 2.22 (1.03-4.81); p = 0.04} and worse disease free survival {OR = 2.19 (1.06-
4.53); p = 0.03}, compared to low DR4 expression. High DR5 expression was associated with 
better survival with borderline significance {OR = 0.65 (0.41-1.03); p = 0.07}. Within the 
group of patients with recurrent disease, the time to recurrence was longer for those with 
high DR5 expression (p = 0.03) or high TRAIL expression (p = 0.007) compared to those 
with low DR5 or TRAIL expression levels. The finding that most tumours showed high 
DR4 and DR5 expression indicates that rhTRAIL may potentially be used as an adjunct to 
adjuvant chemotherapeutic treatment of stage III colon cancer patients.
Recently, two randomised placebo-controlled trials were published showing a 
chemopreventive effect of aspirin in patients with previous colorectal adenomas or 
carcinomas 8,9. These studies were discussed in Chapter 7, and mechanisms behind the 
chemopreventive action against colorectal cancer development of NSAIDs were briefly 
reviewed. Both studies indicated a moderate chemopreventive effect of aspirin in these 
populations. The anticancer properties of NSAIDs have been demonstrated in vitro as 
well as in vivo (animal studies, epidemiological reports, and intervention studies). Several 
mechanisms through which NSAIDs alter colorectal carcinogenesis have been elucidated, 
including the induction of apoptosis in neoplastic cells, via mechanisms dependent and 
independent of cyclo-oxygenase. The exact mechanisms involved in apoptosis induction are 
unknown but recent evidence suggests that sulindac-induced apoptosis involves DR5.
There is also evidence suggesting that NSAIDs work by modulating the Wnt-pathway. 
The formation of adenomas in the intestine is thought to be initiated by mutational events 
occurring in either APC or the gene for β-catenin, both operating in the Wnt-signalling 
pathway. In normal cells, β-catenin is membrane bound, with cytoplasmic β-catenin being 
degraded by the APC/axin/GSK3β-complex. Loss of functional APC or mutations in the 
β-catenin gene lead to the nuclear accumulation of β-catenin, which binds and activates 
the transcription factor T-cell factor 4 (TCF4). Consequently, activated TCF4 activates a 
genetic programme that is presumed to be responsible for early adenoma formation. The 
importance of the Wnt-pathway in which β-catenin/TCF4 activity acts as a switch controlling 
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proliferation versus differentiation in the intestinal epithelium seems critical in the early 
development of colorectal neoplasia. It has been shown that activated Wnt-signalling 
decreases concentrations of the cell cycle regulating protein p21, thereby allowing cells to 
proliferate. Recent evidence suggests that part of the chemopreventive effect of sulindac 
is mediated via p21. For example, microarray data of rectal biopsy specimens and colonic 
cells in culture showed that sulindac induced expression of p21. Furthermore, homozygous 
inactivation of p21 in APCmin mice (the mouse model of FAP) eliminated the ability of 
sulindac to reduce the number of small intestinal tumours in these mice. So, p21 could be 
the link between the Wnt pathway and the chemopreventive effect of sulindac on intestinal 
adenoma formation. 
These data served as the background for studying the effects of sulindac on apoptosis and 
expression of DR4 and DR5, β-catenin and p21 in normal appearing colon mucosa. The 
results are described in Chapter 8. Biopsies obtained before and after sulindac treatment 
during two chemoprevention studies 10,11 were collected. Patients (n = 18) with HNPCC had 
received 150 mg sulindac twice daily for 4 weeks in a placebo-controlled cross-over design. 
Patients (n = 6) with FAP had received 150 mg sulindac twice daily for 6 months. Apoptosis 
was assessed by M30 immunoreactivity and expression patterns of DR4, DR5, β-catenin 
and p21 were studied by immunohistochemistry.
In HNPCC patients, apoptotic indices were similar following placebo and sulindac. 
Also in FAP patients, apoptotic indices were not different after sulindac compared to pre-
treatment values. Expression of DR4 and DR5 was observed in all samples with no consistent 
differences following sulindac versus placebo/baseline. Intensity of membranous β-catenin 
staining was lower in HNPCC samples following sulindac compared to placebo (p < 0.001). 
Similar results were obtained in FAP samples (p < 0.01). p21 expression before and after 
sulindac treatment was similar, in both patient groups. In conclusion, sulindac inhibits 
β-catenin expression in normal colorectal epithelium from HNPCC and FAP patients 
without affecting apoptotic indices and DR4, DR5 and p21 expression. An inhibiting effect 
of sulindac on β-catenin expression has also been observed in APCMin mice as well as in 
human adenomas. Whether this phenomenon is important in the chemopreventive effects 
of sulindac remains to be investigated.
Conclusions and future perspectives
Several genes that regulate apoptosis are inappropriately expressed or mutated in 
colorectal cancer. Although the idea of decreased apoptosis during colorectal cancer 
development is conceptually attractive, the available evidence from in vivo material suggests 
that the proportion of apoptotic cells increases gradually during the adenoma-carcinoma 
sequence. In vitro, tumour progression is usually associated with resistance to apoptosis 
induction. Although these data seem contradictory at first sight, and potentially confusing, 
they are not conflicting. The contradiction resolves when one realises that in vivo studies 
describe spontaneous apoptosis whereas in vitro studies describe induced apoptosis, whether 
by chemotherapy or other agents. Considering the limitations of the current methods of in 
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situ end labelling of DNA fragments, used in the vast majority of in vivo studies, improved 
diagnostic criteria for the identification of apoptotic cells are needed and can be expected 
in the near future. The results from this thesis using the method of M30 immunoreactivity 
support its use in the study of apoptosis in colorectal tissues.
Successful nonsurgical elimination of cancer cells ultimately involves apoptosis. Essentially 
all cytotoxic drugs work by induction of apoptosis, usually not only of malignant cells but 
also of normal cells, manifested by toxicity. Over the last years, knowledge has increased of 
mediators of apoptosis in colon cells, which are dysregulated in tumour cells, such as Bcl-2 
family members and IAPs 12. These suppressors of apoptosis have become targets for drug 
development aimed at restoring apoptosis sensitivity of tumour cells. Alternatively, one 
can imagine strategies aimed at direct activation of agonists of apoptosis, via the extrinsic 
pathway. Unlike its family members TNF and FasL, TRAIL is not associated with induction 
of sepsis and hepatotoxicity respectively. Based on preclinical toxicity and activity data and 
the results described in this thesis showing broad expression of the pro-apoptotic TRAIL 
receptors in colorectal neoplasms, recombinant human (rh) TRAIL is considered of great 
interest for clinical use. Agonistic TRAIL receptor antibodies, directed towards the death 
receptors DR4 and DR5 have shown to exert the same effects as rhTRAIL 13,14. The first phase-
I trials using rhTRAIL and agonistic TRAIL receptor antibodies are underway and results 
from these studies will indicate the value of these agents as anticancer therapeutics.
Furthermore, combination regimens including rhTRAIL should be explored. Findings 
from several reports indicate that the combination of rhTRAIL with certain chemotherapeutic 
drugs, NSAIDs, proteasome inhibitors and interferon-γ all induce apoptosis in an additive 
or synergistic fashion 15. Another intriguing approach is the development of bi-specific 
antibodies. Bi-specific antibodies combine immune cell activation with tumour cell 
recognition, as a result of which pre-defined effector cells kill tumour cells. Recently, a 
technique that combines EGFR-signalling inhibition with target cell-restricted apoptosis 
induction using a TRAIL fusion protein with engineered specificity for EGFR showed 
promising results 16. Analogously, a TRAIL fusion protein with specificity for the 
carcinoma-associated antigen EGP2 has been developed 17. Such combination strategies 
potentially reduce the dose of TRAIL required for anti-tumour activity and should be further 
explored.
Apart from the possible future application of TRAIL in colorectal cancer, there may also be 
a potential role in treatment or prevention of adenomas. Although adenomas are generally 
removed during endoscopy, there are situations in which this cannot be accomplished. 
For example, large, flat sessile adenomas sometimes cannot be removed for technical 
reasons. Another example is the vast number of adenomas that is usually encountered in 
FAP patients, which precludes endoscopic removal. Recent data show that TRAIL also has 
apoptosis-inducing effects on colon adenoma cells 18. This has been confirmed in a study in 
which adenoma cell lines and ex vivo cultures of human adenomas were examined 19. The 
finding in Chapters 4 and 5 of this thesis of expression of TRAIL receptors DR4 and DR5 
in colorectal adenomas supports further investigation of rhTRAIL or other TRAIL receptor 
agonistic agents in the treatment of adenomas.
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In conclusion, new treatment options for CRC have been developed based on insights into 
mechanisms involved in the regulation of apoptosis. The potential clinical application of 
rhTRAIL or other TRAIL receptor agonistic agents in the treatment of colorectal adenomas 
and carcinomas, not only in sporadic cases but even more so in the setting of hereditary 
predisposition syndromes, should be further explored. Results from the first phase-I studies 
with rhTRAIL and TRAIL receptor agonistic antibodies are eagerly awaited and should 
guide future therapeutic strategies. The key to further improvement of prevention and 
therapeutic strategies for colorectal neoplasms is probably not to search for the Holy Grail: 
one ideal anticancer agent. Rather, it is the hunt for defining the optimal combination 
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